皓元医药发布2024年度ESG报告 以创新与责任驱动可持续发展

Core Viewpoint - The company, Shanghai Haoyuan Pharmaceutical Co., Ltd., has released its 2024 ESG report, highlighting its commitment to sustainable development in the biopharmaceutical industry through responsible operations, customer empowerment, and green development [1][2]. Group 1: ESG Governance and Management - The company has integrated ESG into its daily management system, establishing a three-tier governance structure consisting of the Board of Directors, Strategic Committee, and ESG Working Group [1]. - The company emphasizes investor relations management, maintaining close communication with investors through various channels to enhance their confidence in the company [1]. Group 2: Employee Development and Social Responsibility - The company adopts a "people-oriented" approach, strengthening the construction of a "learning organization" and developing a comprehensive training system covering the entire career lifecycle [1]. - The company actively engages in public welfare initiatives and collaborates with industry partners to build an ecological system, promoting sustainable development through technology sharing and resource integration [1]. Group 3: Environmental Commitment - The company incorporates environmental protection concepts throughout its production and operations, responding to concerns about climate change from stakeholders [2]. - The company ensures a 100% compliance rate for "three wastes" (waste gas, waste water, and solid waste) through optimized production processes and enhanced environmental monitoring [2].